Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.

Summary

Using a large patient-derived organoid biobank and single-cell profiling, the authors identify a basal-shift phenotype—driven by NKX2-1 loss—that confers EGFR-TKI resistance in lung adenocarcinoma and creates a therapeutic vulnerability to CDK4/6 inhibitors, particularly in tumors with CDKN2A/B loss. This mechanistic insight fills a major gap for resistance without canonical mutations.

Key Findings

• Defined a basal-shift phenotype in EGFR-TKI–resistant LUAD organoids lacking known resistance mutations.
• NKX2-1 knockout induced basal-shift transformation and EGFR-targeted therapy resistance.
• Basal-shift LUADs frequently exhibited CDKN2A/B loss and were sensitive to CDK4/6 inhibitors.

Clinical Implications

For EGFR-mutant LUAD with NKX2-1 loss/basal-shift and CDKN2A/B loss, CDK4/6 inhibition merits clinical investigation as a resistance-overcoming strategy. Pathology and transcriptomic profiling could stratify patients for such trials.

Limitations

• Predominantly preclinical data; clinical validation in patient cohorts is needed.
• Biomarker thresholds and prevalence of basal-shift across unselected clinical populations remain to be established.

Future Directions

Prospective biomarker-driven trials testing CDK4/6 inhibitors in EGFR-TKI–resistant basal-shift LUAD; multi-omic profiling to define diagnostic criteria and prevalence.